JAK3 has further been observed to be constitutively activated in a range of lymphoid malignancies even when not mutated, such as a cohort of peripheral T cell lymphoma (PTCL) patients positive for ALK [31], underpinning its central role in T cell malignancies. Here, JAK3 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.